Apr 1, 2012 – A quantitative approach to enhancing risk assessment and mitigation in drug development. Regulatory authorities routinely conduct inspections to ensure compliance with good clinical practice (GCP) in the conduct of clinical trials sponsored by pharmaceutical companies.

Jan 19, 2016 – A right implementation of a robust risk assessment process empowers a study management team to better identify and evaluate the right risks for a clinical trial, all while maintaining the appropriate controls to ensure effective and efficient quality conduct, patient safety and regulatory compliance.

“Reflection paper on risk based quality management in clinical trials”. The focus of the regulators on this concept initiates a discussion of how to introduce, implement, and apply risk managementprinciples to clinical trials. The applicable guidances for good clinical practice. (GCP), ICH E6 and ISO14155, state explicitly that …

How to Build Risk Management into Clinical Trials. We live in an age where we wish to de-risk our investments. Today in the highly competitive pharmaceutical sector, if you don’t spot potential risks before they become a danger to the patient, and a regulator can prove you had the information to mitigate them, you are liable …

Some host organisations may not be in a position to undertake the role of sponsor for Clinical Trials of Investigational Medicinal Products (CTIMPs) or may only sponsor trials of a certain risk level. It is essential therefore that they are involved at an early stage and that a risk assessment is undertaken at the very start.

Apr 25, 2017 – management in clinical trials iv, and also the ICH E6 GCP R2 addendum. This document, based on the requirements of the Regulation, provides further information on how such arisk proportionate approach can be implemented and also highlights the areas identified in the. Regulation which allow such …

Mar 5, 2013 – The following risk assessment has been developed on a trial with IMP status of Type A by working with the trial research fellow on behalf of the co-sponsors, which are the Liverpool … It is clear how the risks of the IMP have been evaluated as no more than normal clinical practice based on the SPC.

Nov 22, 2016 – Pharmaceutical companies and clinical study organizations recognize Quality Assurance (QA) and Quality Control (QC) as extremely vital. They are critical not only to drug development and other related research processes but to patients’ safety as well. In this regard, sustaining quality, precision and …

Nov 22, 2016 – Pharmaceutical companies and clinical study organizations recognize Quality Assurance (QA) and Quality Control (QC) as extremely vital. They are critical not only to drug development and other related research processes but to patients’ safety as well. In this regard, sustaining quality, precision and …

Are you prepared for Quality Risk Management (QRM), Risk Management (RM), Risk-Based Quality Management (RBQM)? With ICH GCP E6 R2 now requiring risk-based approaches to managing quality in clinical trials, this 10-Week series takes you through, step-by-step, how to execute these requirements. We will focus …